medigraphic.com
Colegio de Medicina Interna de México.

2009, Número 4

<< Anterior Siguiente >>

Med Int Mex 2009; 25 (4)


Enfermedad de Alzheimer: una panorámica desde su primera descripción hacia una perspectiva molecular

García S, Coral VRM, Meza DE, Lucino CJ, Martínez SB, Villagómez OAJ

Idioma: Español
Referencias bibliográficas: 45
Paginas: 300-312
Archivo PDF: 991.93 Kb.


RESUMEN

Antecedentes: la enfermedad de Alzheimer la describió, a principios del siglo XX, Alois Alzheimer. Representa la primara causa de demencia en el mundo. Se desconoce su etiología pero en su génesis participan factores genéticos ampliamente estudiados y ambientales menos definidos.
Objetivo: investigar en la bibliografía los aspectos históricos y moleculares de vanguardia de la enfermedad de Alzheimer.
Método: búsqueda en libros de historia de la medicina europea mediante el buscador Goggle. Para la revisión de biología molecular se examinaron los servidores de Medline y Ovid con palabras clave: “biología molecular” ,“enfermedad de Alzheimer”, “fisiopatología enfermedad de Alzheimer”, “patología enfermedad de Alzheimer”, “genética enfermedad de Alzheimer” de los años 1989 a 2009. La búsqueda se restringió a: revisiones, investigaciones sólidas e investigaciones de líderes en cada uno de los temas mencionados.
Resultados: entre más de 10,700 artículos se seleccionaron 49 que cumplieron con los criterios señalados.
Conclusiones: El depósito del A-beta amiloide es la piedra angular en la patogénesis de la enfermedad a la que le sigue una cascada de cambios intra y extraneuronales que culminan con la muerte celular.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jalbert JJ, Daiello LA, Lapane KL. Dementia of the Alzheimer type. Epidemiol Rev 2008;30:15-34.

  2. American Psychiatric Association, Committee on Nomenclature and Statistics: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington: American Psychiatric Association, 1994.

  3. Whitehouse PJ, Patterson MB, Strauss ME, Geldmacher DS, et al. Hallucinations. International Psychogeriatrics 1996;8(3):387-91.

  4. Mardsen CD, Harrison MJG. Outcome of investigation of patients with presenil dementia. Br Med J 1972;2:249-52.

  5. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebral Cortex 1991;1:103-16.

  6. Rodríguez-Leyva A. Generalidades y fisiopatología de la enfermedad de Alzheimer. En: Dávila Maldonado L. García S, eds. Temas de Medicina Interna. México: McGraw-Hill Interamericana, 2002;pp:103-17.

  7. Haass C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993;75:1039-42.

  8. Cummings JL. Alzheimer’s disease. N Engl J Med 2004;352:56-67.

  9. Saitoh T, Sundsmo M, Roch J, Ximura M, et al. Secreted form of amyloid p protein precursor is involved in the growth regulation of fibroblasts. Cell 1989;58:615-22.

  10. Ramsden M, Plant LD, Webster NJ, Vaughan PF, et al. Differential effects of unaggregated and aggregated amyloid beta protein (1-40) on K(+) channel currents in primary cultures of rat cerebellar granule and cortical neurons. J Neurochem 2001;79:699-712.

  11. Ramsden M, Henderson Z, Pearson HA. Modulation of Ca2+ channel currents in primary cultures of rat cortical neurons by amyloid p protein (1-40) is dependent on solubility status. Brain Res 2002;956:254-61.

  12. Kamenetz F, Tomita T, Hsieh H, Seabrook G, et al. APP processing and synaptic function. Neuron 2003;37:925-37.

  13. Tanzi RE, Kovacs DM, Kim T-W, Moir RD, et al. The presenilin genes and their role in early-onset familial Alzheimer’s disease review 1996;1:91-98.

  14. Funato H, Yoshimura M, Kusui K, Tamaoka A, et al. Quantitation of amyloid beta-protein (A-beta) in the cortex during aging and in Alzheimer's disease. Am J Pathol 1998;152:1633-40.

  15. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, et al. Amyloidprotein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999;274:25945-52.

  16. Simmons LK, May PC, Tomaselli KJ, Rydel RE, et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 1994;45:373-9.

  17. Taner ENT, Younkin LH, Yager DM, Parfitt F, et al. Plasma amyloid-protein is elevated in late-onset Alzheimer disease families. Neurology 2008;70:596-606.

  18. Pendlebury WW, Solomon PR. Alzheimer’s disease. Clin Simposia 1996;48(3):2-32.

  19. DeKosky ST, Harbaugh RE, Schmitt FA, Bakay RE, et al. Cortical biopsy in Alzheimer’s disease: diagnostic accuracy and neurochemical, neuropathological and cognitive correlations. Ann Neurol 1992;32(5):625-32.

  20. Braak H, Braak E. Neuropathological staging of Alzheimer’s disease. Acta Neuropath 1991;82:239-59.

  21. Ohm TG, Müller H, Braak H, Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience1995; 64(1):209-17.

  22. Honer WG, Dickson DW, Gleeson J, Davies P. Regional synaptic pathology in Alzheimer’s disease. Neurobiol Aging 1992;13(3):375-82.

  23. Stokin GB, Lillo C, Falzone TL, Brusch RG, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005;307(5713):1282-8.

  24. Masliah E, Terry RD, Alford M, DeTeresa R. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer’s disease. Am J Pathol 1991;138:235-46.

  25. Zhan S, Beyreuther K, Schmitt H. Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. Dementia 1993;4(2):66-74.

  26. Su JH, Kesslak PJ, Head E, Cotman CW. Caspase-cleaved amyloid precursor protein and activated caspase-3 are colocalized in the granules of granulovacuolar degeneration in Alzheimer's disease and Down's syndrome brain. Act Neurophat 2002;104(1):1-6.

  27. Levi-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-77

  28. Selkoe DJ. Defining molecular targets to prevent Alzheimer's disease. Arch Neurol 2005;62:192-5.

  29. Guyant-Maréchal L, Rovelet-Lecrux A, Goumidi L, Cousin E, et al. Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology 2007;68:684-7.

  30. Hendriks L, van Duijn CM, Cras P, Cruts M, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the b-amyloid precursor protein gene. Nature Genet 1992;1:218-21.

  31. Fujigasaki H, Naruse S, Kaneko K, Hirasawa H, et al. Mutational analysis of the amyloid precursor protein gene in Japanese familial Alzheimer’s kindreds. Hum Genet 1994;93:460-2.

  32. Hutton M, Hardy J. The presenilins and Alzheimer’s disease. Hum Mol Genet 1997;6:1639-46.

  33. Scheff SW, Price DA. Synaptic density in the inner molecular layer of the hipocampal dentate gyrus in Alzheimer disease. J Neuropathol Exp Neurol1998;57(12):1146-53.

  34. Kavvoura FK, McQueen MB, Khoury MJ, Tanzi RE. Metaanalysis evaluation of the potential excess of statistically significant findings. In: Published genetic association studies: Application to Alzheimer’s disease.

  35. Roses AD. Apolipoprotein E in neurology. Curr Opin Neurol 1996;9(4):265-70.

  36. Myers RH, Schaefer EJ, Wilson PWF, D’Agostino R, et al. Apolipoprotein E E4 associated with dementia in a population-based study: The Framingham Study. Neurology 1996;46:673-7.

  37. Gomez-Isla T, West HL, Rebeck GW, Harr SD, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer’s disease. Ann Neurol 1996;39(1):62-70.

  38. Morishima-Kawashima M, Oshima N, Ogata H, Yamaguchi H, et al . Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol 2000;157:2093-9.

  39. Gomez IT, West HL, Rebeck GW, Harr SD, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer’s disease. Ann Neurol 1996;39(1):62-70.

  40. Prasad KN, Cole WC, Hovland AR, et al. Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale. Curr Opin Neurol 1999;12(6):761-70.

  41. Shimohama SH. Apoptosis in Alzheimer's disease-an update. Apoptosis 2000;5(1):9-16

  42. Passani MB, Bacciottini L, Mannaioni PF, Blandina P. Central histaminergic system and cognition. Neurosci Biobehav Rev 2000;24(1):107-13.

  43. Yamamoto S, Hirano A. Nucleus raphe dorsalis in Alzheimer’s disease: neurofibrillary tangles and loss of large neurons. Ann Neurol 1985;17:573-7.

  44. DeKosky ST. Pathology and Pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc 2003;51(2):S314-S320.

  45. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 2002;36(12):1307-13.




2020     |     www.medigraphic.com